Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 31, 2009

PsychoGenics to Assess AstraZeneca Candidates for Treating Central Nervous System Disorders

  • AstraZeneca signed on PsychoGenics to evaluate a number of its drug candidates for their potential to treat psychiatric disorders. The company will use its high-throughput drug discovery platforms that combine behavioral neurobiology with robotics, bioinformatics, and computer vision.

    PsychoGenics will receive research payments and milestones commensurate with the stage of development. The company is also entitled to royalties on any future sales.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »